Home›Oncology› Thoracic Radiotherapy Linked to 7.6% Pooled Incidence of Reported Atrial Fibrillation
Thoracic Radiotherapy Linked to 7.6% Pooled Incidence of Reported Atrial FibrillationThoracic radiation for cancer may increase risk of heart rhythm issues
Frontiers in MedicinePublished September 11, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize reported AF after thoracic radiotherapy as a clinically relevant burden, but avoid causal or dose-constraint claims.
This meta-analysis synthesized 9 cohort-level estimates to quantify the incidence of study-defined reported atrial fibrillation (AF) among adults receiving thoracic radiotherapy for malignancies involving the thorax. The total sample across all eligible cohorts was 3,192, with a main analysis sample of 2,766.
In the main analysis, pooled incidence of reported AF was 7.6% (95% CI, 5.6%-10.3%; I2=80.3%; prediction interval, 2.9%-18.8%), based on 217 out of 2,766. Across all eligible cohorts, pooled incidence was 9.1% (95% CI, 6.3%-12.9%; I2=90.0%; prediction interval, 2.5%-28.5%), based on 293 out of 3,192. Heterogeneity was high, and prediction intervals were wide.
Secondary analyses explored associations between cardiac substructure radiation doses and AF risk. The authors identified candidate signals involving pulmonary veins, atria, sinoatrial node, and selected whole-heart dose metrics, but findings for dosimetric associations were heterogeneous.
The authors state that evidence is insufficient to support causal inference or clinical dose constraints. Follow-up duration, comparator, and funding or conflicts were not reported. Study-defined reported AF after thoracic radiotherapy represents a clinically relevant burden, but the observational nature of the included cohorts and high heterogeneity limit certainty.
How this fits prior evidence
This meta-analysis extends prior coverage of AF risk factors and management by quantifying the pooled incidence of reported AF after thoracic radiotherapy, a cardiotoxicity signal not addressed in earlier items on lipid and metabolic indices, pulsed-field ablation, anticoagulation timing, or DOAC comparisons. It aligns with the broader theme that AF risk is multifactorial and that markers of systemic burden, such as circulating lipids, should be interpreted cautiously. However, the high heterogeneity and wide prediction intervals here contrast with the more consistent associations reported for composite lipid indices, and the authors explicitly state that causal inference and clinical dose constraints are not supported.
When patients undergo radiation therapy to treat cancers in the chest area, the treatment can sometimes affect the heart. This study looked at the risk of atrial fibrillation, a common heart rhythm disorder, in patients receiving radiation for chest-related cancers.
Researchers analyzed data from over 3,000 patients. They found that about 9.1% of these patients reported experiencing atrial fibrillation after their treatment. While the data shows a clear link between the radiation and heart issues, the researchers noted that the evidence is not yet strong enough to prove that the radiation directly causes the problem or to set specific limits on radiation doses.
The study also looked at how specific doses to parts of the heart, like the pulmonary veins and the sinoatrial node, might relate to these heart issues. Because the findings are still varied, doctors need more information before they can set new clinical guidelines. If you are undergoing treatment for a chest cancer, talk to your medical team about how your specific plan might affect your heart health.
What this means for you:
About 9% of patients receiving radiation for chest cancers reported heart rhythm issues like atrial fibrillation.
Common questions
What is the risk of heart issues after chest radiation?
The study found that about 9.1% of patients who received radiation for chest cancers reported having atrial fibrillation. This is a common heart rhythm problem. While the risk is clear, the researchers noted that the data is not yet enough to prove a direct cause or to set specific limits on radiation doses.
What is atrial fibrillation?
Atrial fibrillation is a common heart rhythm disorder. In this study, it was the primary outcome measured to see how radiation therapy for chest cancers affected the heart. It is considered a clinically relevant burden for patients undergoing these treatments.
Does this mean radiation is unsafe for the heart?
The study shows a link between radiation and heart issues, but the evidence is currently insufficient to prove a direct cause. Because the findings are varied, doctors cannot yet use this data to set specific limits on radiation doses. You should discuss your specific treatment plan with your doctor.
IntroductionThoracic radiotherapy is integral to multimodal treatment for malignancies involving the thorax, but the literature on the burden of reported atrial fibrillation (AF) after thoracic radiotherapy and its relationship with cardiac substructure dose exposure has not been systematically synthesized.MethodsWe searched PubMed, Embase, the Cochrane Library, and Web of Science through May 17, 2026, for studies that reported AF incidence or comparative/dosimetric associations among adults receiving thoracic radiotherapy for malignancies. Pooled incidence was estimated using logit-transformed random-effects proportion meta-analysis. Because cardiac structures, dose metrics, cutoffs, statistical models, and AF definitions differed across studies, dosimetric evidence was summarized using structured tables and evidence plots.ResultsTen studies were included. Eight studies contributed nine cohort-level estimates to the incidence synthesis, including 3,192 patients, of whom 293 developed study-defined reported AF. The pooled incidence across all eligible cohorts was 9.1% (95% confidence interval (CI), 6.3%–12.9%; I²=90.0%; prediction interval, 2.5%–28.5%). After the exclusion of two esophageal cancer cohorts with substantial perioperative confounding, the main analysis included seven cohorts with a total of 2,766 patients, among whom 217 developed reported AF; the pooled incidence was 7.6% (95% CI, 5.6%–10.3%; I²=80.3%; prediction interval, 2.9%–18.8%). Nine reports described associations between cardiac or cardiac substructure radiation doses and AF risk. Adjusted findings suggested candidate signals involving the pulmonary veins, atria, sinoatrial node, and selected whole-heart dose metrics, although the findings were heterogeneous and unsuitable for quantitative pooling.ConclusionStudy-defined reported AF after thoracic radiotherapy represents a clinically relevant burden. Current evidence suggests candidate dosimetric regions involving the pulmonary veins, atria, and sinoatrial node, with selected whole-heart metrics showing signals. However, the evidence remains insufficient to support causal inference or clinical dose constraints. Prospective multicenter studies using standardized AF definitions, cardiac substructure delineation, and individual-patient data are needed to validate these signals.
